Guardant Health ( (GH) ) has released its Q3 earnings. Here is a breakdown of the information Guardant Health presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Guardant Health, a precision oncology company, focuses on enhancing cancer care through advanced blood and tissue tests, real-world data, and AI analytics. In its third-quarter 2025 earnings report, Guardant Health announced a 39% revenue increase, reaching $265.2 million, driven by strong performance in its Oncology, Screening, and Biopharma & Data segments. The company also raised its 2025 revenue guidance to $965 to $970 million, indicating a 31% year-over-year growth.
Key financial highlights include a 31% increase in Oncology revenue to $184.4 million, a significant rise in Screening revenue to $24.1 million, and an 18% growth in Biopharma & Data revenue. The company achieved a non-GAAP gross margin of 66%, up from 63% the previous year. Operating expenses rose to $270.6 million, primarily due to the expansion of the commercial team and marketing efforts for the Shield product launch.
Guardant Health also made strategic advancements, such as expanding its Shield test to include multi-cancer detection and forming partnerships with Quest Diagnostics and PathGroup to enhance nationwide access. The company reported a net loss of $92.7 million, an improvement from the $107.8 million loss in the prior year, with a non-GAAP net loss of $48.3 million.
Looking ahead, Guardant Health anticipates continued growth, with expectations of a 25% increase in Oncology revenue and a significant rise in Screening revenue. The company remains focused on expanding its commercial infrastructure and strategic collaborations to meet growing demand and advance its mission of improving cancer care.